A 64 - year - old male with history
of Acute Myelogenous Leukemia (AML) status post bone marrow transplant (BMT) in complete remission presented with dyspnea when laying on his right side which resolved when supine or in the left lateral decubitus position.
Not exact matches
It is activated in 50 to 80 percent
of patients with
acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations.
In both
acute and chronic
myelogenous leukemia, immature white blood cells in the bone marrow multiply out
of control.
[3]-RRB- However, the presence
of the Philadelphia (Ph) chromosome is not sufficiently specific to diagnose CML, since it is also found in
acute lymphoblastic
leukemia [4](aka ALL, 25 — 30 %
of adult cases and 2 — 10 %
of pediatric cases) and occasionally in
acute myelogenous leukemia (AML).
A Phase I Study
of DS - 3201B in Subjects with
Acute Myelogenous Leukemia (AML) or
Acute Lymphocytic
Leukemia (ALL)
There was scant experimental evidence for this hypothesis until 1994, when John Dick and colleagues demonstrated that
leukemia - initiating stem cells (LSCs) present in the blood
of leukemia patients may induce
acute myelogenous leukemia (AML) when transplanted into severe combined immunodeficient mice (2).
Antineoplastic mechanisms
of niclosamide in
acute myelogenous leukemia stem cells: inactivation
of the NF - kappaB pathway and generation
of reactive oxygen species.
May 30, 2015 Khoury et al ASCO AST - VAC1 Presentation Long - term Follow - up
of Patients with
Acute Myelogenous Leukemia Receiving an Autologous Telomerase - based Dendritic Cell Vaccine
Autologous HCT is used primarily for the treatment
of diseases such as lymphoma, Hodgkin disease,
acute myelogenous leukemia, myeloma, breast cancer and testicular cancer.
These mutant kinases are attractive therapeutic targets, as demonstrated by the efficacy
of imatinib in BCR - ABL — positive chronic
myelogenous leukemia (CML), 5 as well as in MPD associated with activating alleles involving PDGFRA or PDGFRB.2, 6,7 In addition, activating mutations in the FLT3 receptor tyrosine kinase are the most common genetic event in
acute myeloid
leukemia (AML), and specific inhibitors
of the FMS - like tyrosine kinase 3 (FLT3) have entered late - stage clinical trials.8 Although mutations in tyrosine kinases and in other genes have been identified in a subset
of MPD and AML, in many cases the genetic events that contribute to the molecular pathogenesis
of these diseases remain unknown.
ONC201 demonstrated (GI50 1 - 8 µM) dose - and time - dependent efficacy in
acute myeloid
leukemia (AML),
acute lymphoblastic
leukemia (ALL), chronic
myelogenous leukemia (CML), chronic lymphocytic
leukemia (CLL), diffuse large B - cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T - cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard
of care (dexamethasone in MM) and primary samples.
he study reiterates earlier research which shows that prolonged exposure to airborne petroleum hydrocarbons causes «an increased risk
of eye irritation and headaches, asthma symptoms,
acute childhood
leukemia,
acute myelogenous leukemia, and multiple myeloma.»